Tpg Gp A, LLC and 2 Others Buys $20.3M of Sionna Therapeutics Inc (SION) — SEC Form 4, Feb 12, 2025
Open-Market Net Purchase · SEC Form 4
+$20,250,000
Equity position changed by +876.7%
Reporting Owners
10%+
10%+
10%+
TXN 2025-02-10
·
FILED 2025-02-12
Equity Position
6.68M sh
684,415 → 6,684,962
Equity Change
+876.7%
shares held after vs before
Filing Lag
2 business days
within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership
Reporting Owners
| Name | Relationship |
|---|---|
| Tpg Gp A, LLC CIK 0001903793 |
10% Owner
|
| James G Coulter CIK 0001099776 |
10% Owner
|
| Jon Winkelried CIK 0001366946 |
10% Owner
|
Tpg Gp A, LLC at Sionna Therapeutics Inc
Full insider history
Bought (12 mo)
—
Sold (12 mo)
$10,000,000
More from this insider at Sionna Therapeutics Inc
| 2026-01-26 | Sell | -$10,000,000 | View |
| 2025-07-01 | Buy | +$950,400 | View |
Non-Derivative Securities Transactions
Derivative Securities Transactions
| Title | Strike | Date | Type | Shares | Price | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| Series Seed Preferred StockF3F3F3F3F1F2F3F5F6 | 2025-02-10 | C - Conversion | 1,276,276 D | 873,503 Common Stock | Indirect See Explanation of Responses | |||
| Series A Preferred StockF3F3F3F3F1F2F3F5F6 | 2025-02-10 | C - Conversion | 1,806,318 D | 1,236,272 Common Stock | Indirect See Explanation of Responses | |||
| Series B Preferred StockF3F3F3F3F1F2F3F5F6 | 2025-02-10 | C - Conversion | 2,275,528 D | 1,557,408 Common Stock | Indirect See Explanation of Responses | |||
| Series C Preferred StockF3F3F3F3F1F2F3F5F6 | 2025-02-10 | C - Conversion | 1,765,541 D | 1,208,364 Common Stock | Indirect See Explanation of Responses |
Footnotes (6)
- F1
- Each of James G. Coulter and Jon Winkelried own entities that control TPG GP A, LLC (together with Messrs. Coulter and Winkelried, the "Reporting Persons"), which is the managing member of each of (i) TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., and (ii) Alabama Investments (Parallel) GP, LLC, which is the general partner of each of (a) Alabama Investments (Parallel), LP, (b) Alabama Investments (Parallel) Founder A, LP and (c) Alabama Investments (Parallel) Founder G, LP, which, collectively with TPG Group Holdings (SBS), L.P., Alabama Investments (Parallel), LP and Alabama Investments (Parallel) Founder A, LP, holds 100% of the shares of Class B common stock (which represents a majority of the combined voting power of the common stock) of TPG Inc. Show more
- F2
- TPG Inc. is the sole member of TPG GPCo, LLC, which is the sole member of TPG Holdings II-A, LLC, which is the general partner of TPG Operating Group II, L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Operating Group I, L.P., which is the sole member of The Rise Fund GenPar Advisors, LLC, which is the general partner of The Rise Fund GenPar, L.P., which is the managing member of The Rise Fund SPV GP, LLC, which is the general partner of each of The Rise Fund Sling, L.P., which directly holds 5,476,598 shares of Common Stock ("Common Stock") of Sionna Therapeutics, Inc. (the "Issuer"), and The Rise Fund Sling II, L.P. (together with The Rise Fund Sling, L.P., the "TPG Funds"), which directly holds 1,208,364 shares of Common Stock. Show more
- F3
- Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, as amended, the shares of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock, in each case of the Issuer (collectively, the "Preferred Stock"), automatically converted into shares of Common Stock upon consummation of the Issuer's initial public offering on February 10, 2025 at a conversion rate (adjusted for a reverse stock split) equal to one share of Common Stock per 1.4611 share of Preferred Stock. The shares of Preferred Stock had previously been convertible, at the option of the holder, at any time into shares of Common Stock. Show more
- F4
- On February 10, 2025, in connection with the Issuer's initial public offering, The Rise Fund Sling, L.P. acquired an aggregate of 1,125,000 shares of Common Stock at a price of $18.00 per share. Show more
- F5
- Because of the relationship between the Reporting Persons and the TPG Funds, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of the TPG Funds. Each of the TPG Funds and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such TPG Fund's or such Reporting Person's pecuniary interest therein, if any. Show more
- F6
- Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Show more
Remarks
7. The Reporting Persons are jointly filing this Form 4 pursuant to Rule 16a-3(j) under the Exchange Act. 8. Gerald Neugebauer is signing on behalf of Messrs. Coulter and Winkelried pursuant to authorization and designation letters dated January 10, 2024, which were previously filed with the Securities and Exchange Commission.
Show moreRelated filings at Sionna Therapeutics Inc
Institutional Holders
13F holders · Jun 30, 2026
145
institutional managers reporting a position
Largest by reported value
- Ra Capital Management, L.P. $436M
- Tpg Gp A, Llc $286M
- Viking Global Investors Lp $141M
5%+ Holders · 13D/G
6 filers
-
Orbimed Advisors Llc 6.6%
-
Tpg Gp A, Llc 15.2%
Other insiders at Sionna Therapeutics Inc
GET /v1/forms/4/0001999371-25-001562
API docs
View Original SEC Filing